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Abstract
Voltage-gated sodium channels (Nav) control the initiation and propagation of action
potential, and thus mediate a broad spectrum of physiological processes, including central
and peripheral nervous systems’ function, skeletal muscle contraction, and heart rhythm.
Recent advances in elucidating the molecular basis of channelopathies implicating Nav
channels are the most appealing druggable targets for pain and many other pathology
conditions. This chapter overviews Nav super family from genetic evolution, distribution,
human diseases/pathology association, highlighting the most recent structure function
breakthrough. The second section will discuss current small and large Nav modulators,
including traditional nonselective pore blockers, intracellular modulators, and extracellu-
lar modulators.
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1. Introduction
Voltage-gated sodium channels (Nav) are large transmembrane proteins that conduct the flow
of sodium ions down the electrochemical gradient through cell membranes. In excitable and
nonexcitable cells, these channels control action potential initiation/propagation, cell motility,
and proliferation. Na+ currents were firstly discovered in 1949 by Hodgkin and Huxley in their
study of action potentials in squid giant axon [1, 2]. This early work demonstrated that the
resting membrane potential mostly depends on potassium permeability, whereas action poten-
tial is directly shaped by sodium permeability, which allows transient influx of Na+ to raise
membrane potentials and is followed by rapid inactivation within milliseconds. From 1950s to
1970s, studies from many laboratories established conceptual models and equations conceptu-
alizing sodium channel function [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Membrane potential, Nernst and Goldman equations
In a typical cell, sodium, potassium, chloride, and other membrane permeable ions are in
unequal distribution across plasma membrane, Figure 1A. This unequal distribution and its
resultant electrical gradient can be explained by Donnan equilibrium. For a specific ion, the
electrical potential difference that exactly counterbalances diffusion due to the concentration
difference is called the equilibrium potential for that specific ion. To use Na+ as an example, at
equilibrium, the chemical force moving Na+ into the cell is balanced by the electrical force
moving Na+ out of the cell (Figure 1B).
For each ion, the equilibrium (or reversal) potential, Eion, can be calculated by the Nernst
equation (Eq. (1)), where R = gas constant, 8.135 J K1 mol1; T = temperature in K (273 + temp
in oC); z = valency of ion (Na+ = 1, Ca2+ = 2, and Cl =1); F = Faraday’s constant, 9.684 104 C
mol1. In a typical mammalian neuron with [Na+], [K+], and [Cl] described in Figure 1A,
based on Nernst equation, we can calculate ENa = 67 mV, EK = 83 mV, and ECl = 61 mV. In
cell resting state, the experimental measured membrane potential Em = 65 mV. As indicated
in Figure 2, Na+ has a tendency to flow into the cell due to Em < ENa, while K
+ flow out of the
cell (Em > EK), and Cl
 near equilibrium (Em ≈ECl). These concentration and electrical gradi-
ents are maintained by the dynamic equilibrium of ion channels and active ion transporters,
most importantly by sodium pump (Na/K-ATPase).
Eion ¼
RT
zF
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Ion½ out
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(1)
The whole cell membrane potential Em can be calculated by all permeable ions’ equilibrium
potentials Eion and their relative permeability P, which is described by Goldman-Hodgkin-
Katz equation (GHK equation) (Eq. (2)). This equation explained the experimental finding that
resting membrane potential is more depending on PK, which is about 25-folds to PNa.
Figure 1. (A) Unequal distribution of ions in a typical mammalian neuron and (B) Donnan equilibrium scheme shows that
the balance of concentration gradient and electrical gradient drives Na+ movement toward inside or outside of the cell.
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1.2. Hodgkin-Huxley model
The Hodgkin-Huxley model describes how action potentials in neurons are initiated and
propagated [4]. Originally developed to fit action potential dynamics of squid giant axon, this
model has been successfully applied to a wide range of neurons. It describes the electrical
properties of excitable membranes as typical electrical circuit components. For instance, the
cell membrane is modeled as a capacitor with capacitance (Cm) and ion channels are resistors
with conductance of Na channel (gNaÞ, K channel (gKÞ, and leak channel (gLÞ.
From Hodgkin-Huxley model, the total cell membrane current, I, can be calculated by Eq. (4),
where membrane potential Vm, ion conductances gNa and gK, sodium activation variable m,
sodium inactivation variable h, potassium activation variable n are variable functions of time,
whereas ENa, EK, EL, CM, and gL are constants.
gNa ¼ gNam
3
∞
h0 1 exp 
t
τm
  3
exp 
t
τh
 
(3)
I ¼ Cm
dVm
dt
þ gNam
3h Vm  VNað Þ þ gKn
4 Vm  VKð Þ þ gL Vm  VLð Þ (4)
Hodgkin-Huxley model provides a relatively simple and experimentally testable equation to
deduce Na+ conductance change with time and voltages (Figure 2B), and nerve action poten-
tial (Figure 2C). It also embodies the three key features of Nav channels: voltage-dependent
activation (submillisecond scale), rapid inactivation (millisecond scale), and selective Na+
conductance.
Figure 2. (A) Hodgkin-Huxley model, modified from Wikipedia. (B) Changes of sodium conductance associated with
different depolarization voltages at 10, 51, and 100 mV. The circles are experimental sodium conductance, and the smooth
curves are theoretical curves. (C) Calculated gNa, gK components of total membrane conductance (g) during propagated
action potential (dV). Modified from [4].
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1.3. History and basic concepts of electrophysiology
Electrophysiology was originated by Luigi Galvani in studying “animal electricity” in 1780s.
In 1903, an extracellular recording technique, electrocardiography, was invented by Willem
Einthoven (1924 Nobel Laureate); in 1952, intracellular recording technique was developed by
Alan Hodgkin and Andrew Huxley (1963 Nobel Laureates); and in 1976, Erwin Neher and
Bert Sackmann (1991 Noble Laureates) succeeded in measuring the ionic current of single
channels in the cell membrane by developing patch clamp technique. These works were
fundamental in revealing the physiological function of ion channels. Since then, the field of
electrophysiology had undergone rapid evolution, especially after the introduction of auto-
mated patch clamp in the early 2000s.
Manual patch clamp technique employs glass microelectrode(s) with desired filling solution
and tip diameter to perform either voltage or current clamp. For larger cells, such as Xenopus
oocytes, two-electrode voltage clamp (TEVC) is performed using two electrodes: one to mea-
sure membrane potential and the other to apply the current, with each tip diameter <1 μm
resulting in 10–100 MΩ resistances. For most other circumstances, a single electrode with an
open tip diameter 1–3 μm (1–3 MΩ resistances) is used for whole cells or small patches of cell
membrane recording. A typical patch-clamp recording starts with cell attaching procedures
including: placing glass tip next to a cell, using gentle suction, drawing a piece of the cell
membrane to the microelectrode tip, and then letting glass tip to form a high-resistance seal
with the cell membrane (ideally >1GΩ, so-called “gigaseal”). By applying different following-
up manipulations, the patch-clamp can be achieved in four configurations: cell-attached patch,
whole-cell patch, inside-out patch, and outside-out patch, as shown in Figure 3.
Figure 3. Manual patch clamp configurations and procedures. After a cell is approached by a pipette (A), a high-
resistance seal is achieved through application of negative pressure, resulting in the cell-attached configuration (B).
Further application of negative pressure ruptures the membrane, resulting in the whole-cell configuration, i.e., electrical
contact with the inside of the cell (C). Inside-out and outside-out configurations are achieved by pulling the pipette away
from the cell (D and E). (F) An equivalent electrical circuit of a cell in whole-cell configuration during acquisition of data.
VM = membrane potential, I = whole current, Rseal = seal resistance, Rs = series resistance, RM = membrane resistance,
CP = pipette capacitance, CM = membrane capacitance. Modified from [5].
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Many other electrophysiological techniques have been developed for various applications,
including extracellular recordings such as electroencephalography (EEG), electrocardiography
(ECG or EKG), and electromyography (EMG) for clinical diagnosis; artificial lipid bilayer
recording for studying activities of reconstituted ion channel proteins; automated patch clamp
recording to enable high-throughput recordings; and optogenetics to employ light to switch on
and off ion channel activities. The technology evolution has brought the ion channel research
and drug discovery to a new era, which will be discussed in later part of this chapter.
2. Nav channel general physiology
Nav channels were the first ion channel family discovered back in 1952 [1, 4] and cloned in
1984 [6]. Its pedigree spans across prokaryotic and eukaryotic kingdoms [7]. To date, 500
Nav channels from bacteria (BacNavs) [8–10], and even more Nav channels from other
species including fly [11], jellyfish [8], electric eel [12], cockroach [13], teleost fishes [8],
and mammals have been cloned [14]. The BacNavs regulate the survival response to
extreme pH, electrophiles, and hypoosmotic shock. Despite their markedly difference in
physiology function, voltage dependence and kinetics, BacNavs share common features of
mammalian Nav channels, thus serving as surrogates in the study of molecular evolution
and channel architecture. Eukaryotic Navs display ultrafast kinetics, with milliseconds
activation to inactivation, and high sodium ion selectivity, Na+ (l): K+ (0.14): Rb+ (0.02): Cs+
(0.005), which together enable them being responsible to initiate and transduce fast action
potential firing in the vast electrical signaling pathways throughout the cardiovascular and
nervous systems.
Nav family belongs to the voltage-gated ion channel (VGIC) superfamily, with less intrafamily
variation comparing to the other two VGIC families, voltage-gated potassium channels (Kvs)
and voltage-gated calcium channels (Cavs). The core functional unit of Nav channel is a
tetrameric complex composed of four homologous domains (DI/II/III/IV), with each domain
containing six transmembrane segments (S1–S6), an intracellular N-terminus and C-terminus.
The first four transmembrane segments form a voltage-sensing domain (VSD) and the last two
form the pore domain (PD). The central PD is responsible for ion-transduction through the
structural top funnel, selectivity filter and gate, and all other domains are served as regulatory
modlues for activation, fast and slow inactivation, albeit with different natures and structures.
Each eukaryotic Nav channel is composed of a single macromolecular α subunit (2000 amino
acid residues, 260 kDa), forming a pseudoheterotetrameric core functional unit, in associa-
tion with one or more auxiliary β subunits (β1, β2, β3, and/or β4, 35 kDa) [15] (Figure 4).
While the prokaryotic Navs are formed by four separate α subunit, similar to Kv channels,
representing a simpler construction than eukaryotic Navs. A typical Nav channel has at least
three distinct states, resting (closed), activated (open), inactivated (closed), which itself
includes fast-inactivated (within milliseconds) and slow-inactivated (seconds), and recovering
from inactivation (repriming), which is a period in which the channel is not available to open
in response to a depolarization. Each Nav channel can be characterized by these different
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voltage-dependent biophysiological preporties, and pharmacological perporties according to
its expression pattern and modulation.
In human, there are 9 Nav channels (Nav1.1-1.9), which are encoded by the genes SCN1A,
SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SCN10A, and SCN11A, respectively.
A tenth isoform, Nax, is considered as atypical, as it contains key difference in DI/III/IV S4 VSDs
and DIII-IV inactivation linker, also it is activated by augmentation of extracellular sodium (over
150 mM) instead of voltage. Thus, Nax was classified as a different Nav subfamily (type 2)
[16, 17]. Based on the timeline of gene cloining, each α subunit gene was assigned as SCN1A to
SCN11A, and likewise, auxiliary β subunit genes were assigned as SCN1B to SCN4B, respec-
tively (Table 1).
Due to their fundamental role in regulating central and peripheral nervous systems function,
skeletal muscle contraction and heart rhythm, much of the early works on Navs involved
characterizing their expression patterns, biophysiological properties, structure-function, and
molecular pharmacology.
Figure 4. Structures of voltage-gated sodium channels. Modified from [12, 15]. (A) Schematic representation of BacNav.
(B) Schematic representation of eukaryotic Navs. (C and D) The top and side views of the cryo-EM structure of EeNav1.4-
β1 complex (PDB 5XSY). The α-subunit domains DI-IV are colored orange, yellow, cyan, and blue, respectively, and the β1
subunit is colored red. (E) The pore domain sodium permeation path including selectivity filter, central cavity, and
intracellular activation gate are colored in brown and annotated with pore radius.
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2.1. Genetic evolution and expression
Compared to Cav and Kv channel family, the rise of Nav family is relatively recent [18].
The study of intron/exon organization suggested that Navs were evolved from the similarly
structured Cav channels. This is supported by the finding that the four domains of Navs have
higher similarity to their corresponding domains in the Cav channels than to each other.
The ancestral Navs and Cavs genes might have evolved by two rounds of gene duplication,
i.e., from an ancestral, single-domain Kv-like gene to a two-domain protein, then from a
two-domain protein to a four-domain protein. This hypothesis is also in line with the observa-
tion that among the four domians of Navs, DI shares higher similarity with DIII, and DII
shares higher similarity to DIV [19].
hNav
isoform
Gene Variant(s) Human
chromosome
locus
UniProt Homology* TTX
IC50
(nM)
Primary tissue
location
Therapeutic
relevance
Nine voltage-gated α subunits
Nav1.1 SCN1A 3 2q24 P35498 90.0% 6 CNS, PNS Epilepsy
Nav1.2 SCN2A 2 2q23–24 Q99250 90.8% 12 CNS, glia Epilepsy, autism
Nav1.3 SCN3A 4 2q24 Q9NY46 90.0% 4 CNS, glia Epilepsy
Nav1.4 SCN4A 1 17q23–25 P35499 76.8% 5 Skeletal muscle Myotonia
Nav1.5 SCN5A 6 3p21 Q14524 79.4% 2000 Cardiac muscle Cardiac rhythm
disorders
Nav1.6 SCN8A 5 12q13 Q9UQD0 85.9% 1 CNS, PNS, glia Ataxia, motor
neuron disease
Nav1.7 SCN9A 4 2q24 Q15858 100% 4 Sensory neurons Pain
Nav1.8 SCN10A 1 3p21–24 Q9Y5Y9 77.0% 60,000 Sensory neurons Pain
Nav1.9 SCN11A 3 3p21–24 Q9UI33 70.4% 40,000 Sensory neurons Pain
One nonvoltage-gated α subunits
Navx SCN7A** 1 2p21-23 Q01118 71.2% PNS, DRG, epithelia
Four β subunits
Navβ1 SCN1B 2 19q13 Q07699 100% CNS, PNS, muscle Epilepsy
Navβ2 SCN2B 1 11q23 O60939 53.1% CNS
Navβ3 SCN3B 1 11q23 Q9NY72 72.0% CNS
Navβ4 SCN4B 3 11q23 Q8IWT1 57.9% CNS, thyroid
Data from Universal Protein Resource (UniProt, http://www.uniprot.org).
*α-subunit homology is calculated as the similarity between the most abundant isoform variant to Nav1.7 variant 3, which
is the canonical sequence and position reference.
**SCN6A and SCN7A are orthologs of a single atypical Nax gene (SCN7A in mouse, the same gene was denoted as
SCN6A in human).
Table 1. Human Nav channel subunits’ gene information.
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In choanoflagellate (the sister group of animals), the rapid long-distance communication
among excitable cells is achieved at the emergence of Metazoa (represented by bilaterian
animals and cnidarians) through the use of Nav channel [20, 21]. The gene organization,
biophysical, and pharmacological properties of invertebrate sodium channels are largely sim-
ilar to their mammalian counterparts, suggesting that the primordial Nav channels were
established before the evolutionary separation of the invertebrates from the vertebrates, and
evolution of Navs played a critical role in the emergence of nervous systems in animals
[19, 22]. Of note, sodium selectivity might be acquired independently in BacNav and mamma-
lian Nav channels as indicated by phylogenetic analysis [23]. Therefore, BacNav channels can
serve as models for studying Navs structure function, but evolutionary variation should be
taken into consideration.
Historically, the tissue distribution of mammalian Nav isoforms was obtained by methods
such as quantitative PCR, expressed sequence tag (EST) profiling, and pharmacology study
using isoform selective toxins. The more precise expression data were recently obtained by
microarray [24, 25] and mRNA sequencing from Genotype-Tissue Expression (GTEx) project
[26] (Figure 5). Now, we know that Nav1.1, Nav1.2, and Nav1.3 are predominantly expressed
in central nervous system (CNS). Nav1.1 is the predominant channel in the caudal regions and
the spinal cord, though relatively low-level expression of Nav1.1 has been shown in the
peripheral nervous system (PNS). Nav1.2 is the highest expression isoform in the rostral
regions. Nav1.3 peaks at birth but remains detectable at a lower level in adulthood. Interest-
ingly, all of these CNS-enriched isoforms are sensitive to tetrodotoxin (TTX) at nanomolar
concentrations, and their genes are clustered on chromosome 2 in both mice and humans.
Nav1.4 and Nav1.5 exhibit strikingly high-level expression in muscle and heart, respectively.
More sensitive approaches have detected Nav1.5 in the piriform cortex and limbic regions of
the brain but at relatively low level [27]. These two Nav isoforms can be distinguished from
each other and from the CNS isoforms on the basis of toxin sensitivity. Adult skeletal
muscle-enriched Nav1.4 is sensitive to TTX and μ conotoxin GIIIA at nanomolar concentra-
tions, while the CNS-enriched channels are only sensitive to TTX, and heart-specific Nav1.5
is resistant to TTX. In addition, Nav1.4 is inhibited by nanomolar concentrations of μ
conotoxin PIIIA, whereas Nav1.2 is approximately 15-fold less sensitive, and Nav1.7 is
resistant [28–30].
Nav1.6 appears to be abundantly expressed in both PNS and CNS tissues. Nav1.7, Nav1.8, and
Nav1.9 are primarily expressed in PNS, including nociceptive neurons, Aβ-fibers, C-fibers, and
both large and small diameter dorsal root ganglion (DRG) [31]. This PNS-specific localization
of Nav1.7, Nav1.8, and Nav1.9 make them attractive targets for developing isoform selective
modulators to treat many PNS-related diseases and pathologic conditions.
2.2. Nav channel structure-function
The core functional unit of Nav channels is α subunit. Each α subtype is composed of a single
polypeptide chain with 2000 amino acid residues forming four pseudoheteromeric domains
designated as DI to DIV. Nine α subunits’ protein sequence homology is greater than 70%
(Table 1). The structure complexity and high-sequence homology make it difficult to design
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Figure 5. Sodium channel body atlas in human. (A and B) Human Nav α and β subunits tissue expression level from
GTEx RNA-seq database (https://www.gtexportal.org). Gene expression level is presented as averaged tissue transcripts
per million (TPM) value from 570 donors’ 8555 samples. (C) Nav α and β subunits’ expression level in human DRG. Gene
expression level is presented as averaged cDNA microrray indensity number from 214 human DRG samples [56].
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subtype-selective drugs. In 2011, the first X-ray crystal structure of bacterial Arcobacter
butzleri Nav channels (NavAb) was determined [32]. Subsequently, structures for several
BacNavs and a BacNav-human Nav chimeric channel have been resolved, representing closed
[33, 34], open [34, 35], and potentially inactive states of the channels [36, 37]. In 2017, the first
two eukaryotic Nav structures for American cockroach and electric eel (Ee) Nav1.4-β1 complex
were determined by using cryogenic electron microscopy (CryoEM) [12]. Findings from crystal
and cryo-EM structures are mostly consistent, and collectively provided important insights
into Nav channel structure-function and structure-based drug design.
Voltage-sensing domains (VSDs). The S1 to S4 segments form voltage-sensing domain. There
are four VSDs in a sodium channel. Each VSD is featured by repetitively occurring positively
charged Lys or Arg residues at every third position in S4. These charge clusters move toward
the extracellular surface upon membrane depolarization and return to their resting positions
upon membrane repolarization. Each VSD is connected to an intracellular S4-S5 linker, which
transfers the movement of S4 segment to the central pore domain formed by S5-S6. Thus, the
outward and inward movements of S4 result in channel opening and closing, respectively.
Unlike homotetrameric Kvs and BacNavs, mammalian Nav channel’s four VSDs possess
distinctive sequence signature, conformation, and role in channel gating [12, 13]. For examples,
the four VSDs have nonconserved intra- and extracellular loops, and the different charge
clusters in S4, i.e., RRRR in DI, RRRRK in DII, KRRRR in DIII, and RRRRR in DIV. Also, the
S2 in each VSD also makes asymmetric functional contributions to Nav channel activation and
inactivation [38].
Pore domain (PD): the S5 to S6 segments from the four domains of the α subunits enclose the
central pore of the channel. The extracellular linker connecting S5-S6 is defined as pore-loop
(P-loop), which can be separated into two α helices named P1 and P2. The functional entities
along the ion permeation pathway in PD include the selectivity filter (SF), the central cavity,
and the intracellular activation gate, as shown in Figure 4E.
The outer vestibule and selectivity filter are formed in P-loop reentering membrane segments,
designated as P1-SF-P2 funnel. Early study by comparing Navs with Cavs found that one
residue, Asp/Glu/Lys/Ala (DEKA), at the corresponding locus in the middle of P1-P2 deter-
mines Na+ selectivity [39]. Structure studies confirmed that the asymmetric selectivity filter
vestibule is constituted by the side chains of the signature DEKA residues and the carbonyl
oxygens atoms of the two preceding residues in each domain, Thr/Gln (DI), Cys/Gly (DII), Thr/
Phe (DIII), and The/Ser (DIV). Mutational study identified an additional outer ring above the
selectivity filter, Glu/Glu/Met/Asp (EEMD), which significantly interfered the tetrodotoxin
(TTX) binding [40, 41]. The outer vestibule and SF structures were further discerned by using
bacteria KcsA channel X-ray structure as template and guanidinium toxins (TTX and saxitoxin,
STX), which successfully defined the first pharmacological relevant site on Nav channels, site 1
[42]. After that, local anesthetic binding site was determined within the four fenestrations in
PD, each with distinct shape and size [13, 43]. From studying a group of activators, including
batrachotoxin (BTX), veratridine (VTD), grayanotoxin (GTX), and aconitine (ACD), the neuro-
toxin site 2 was determined in the inner cavity of PD [44, 45].
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Activation gate: the activation gate of Nav channels was originally predicted to be at the inner
end of the pore based on the study of local anesthetics, which exhibit usage-dependent block-
age [46, 47]. From thiol-modifying reagent accessibility study, a 3.8 Å diameter constriction
formed by a ring of conserved hydrophobic residues at the end of S6 (represented as DI-V440,
DII-L795, DIII-I1287, DIV-I1590 in Nav1.4 and DI-Y405, DII-F960, DIII-F1449, DIV-F1752 in
Nav1.7) was found to occlude only the pore at closed state but not at open state [48]. Recent
cryo-EM structures confirmed that this activation gate is located at the cytoplasmic boundary
level of the membrane [12]. Channelopathy study found that Nav1.7 DII S6 L955 deletion
cause F960 side change conformational change in the activation gate. This mutation produces
radial shift of the channel open at 25 mV more hyperpolarizing voltage, which renders
hyperexcitability of DRG neurons to cause inherited erythromelalgia (IEM) [48].
Fast inactivation: while the channel opening is controlled by VSD and activation gate, the fast
inactivation is regulated by a highly conserved Ile/Phe/Met (IFM) motif, which is localized in
an intracellular loop connecting the domain DIII and DIV [49]. The IFM motif was originally
discovered as a particle segment attached to the inner end of the pore. Study showed that
pronase and N-bromoacetamide removed inactivation only when applied from intracellular
side [50], and acetyl-KIFMK-amide peptides restored fast inactivation [51]. In the eukaryotic
EeNav1.4-β1 structure at open and resting states, the LFM motif (equivalent to IFM) in DIII-IV
linker is plugged into the corner enclosed by the outer S4-S5 and inner S6 segments in DIII and
DIV. Once the channel opens, the LFMmotif acts as a hinged lid and folds into the intracellular
mouth of the open pore to produce fast inactivation.
Slow inactivation: in contrast to fast inactivation (milliseconds scale), slow inactivation occurs
in seconds during prolonged depolarization or rapid repetitive stimulations. Slow inactivation
determines channel availability for action potential generation; thus, it endows neuronal tis-
sues with memory of previous excitation, prevents excitation of skeletal muscle by mild
hyperkalemia, and affects the conduction velocity and excitability of cardiac tissue. For the
cardiac Nav1.5 channel, two putative proton sensor residuals in P-loop, C373 and H880, were
responsible of tissue-acidification-induced slow inactivation underlying cardiac arrhythmia
[52]. Other mutations, including DII S4-S5 linker L689I in Nav1.4, DII S6 Del-L955 in Nav1.7,
have also been identified to impair slow inactivation, causing hyperkalemic periodic paralysis
and inherited erythromelalgia, respectively [53, 54]. Voltage-clamp fluorimetry (VCF) study of
Nav1.4 channels showed that that immobilization of DI and DII VSDs is involved in the
development of slow inactivation, while DIII VSD is involved in the recovery from slow
inactivation [55]. However, the structural basis for slow inactivation remains undefined.
2.3. Nav β subunits
In vertebrates, five Nav auxiliary β subunits, β1, β1B, β2, β3, and β4, have been identified
(SCN1B to SCN4B), with molecular weight ranging from 30 to 40 kD (Table 1) [57–60]. In
invertebrates, auxiliary subunits such as tipE and Vssc β in drosophila bear no homology to
vertebrate β subunits, suggesting a separate evolutionary pathway [61–63]. All β subunits
comprise an amino terminal immunoglobulin (Ig) domain, a single transmembrane (TM)
Voltage-Gated Sodium Channels in Drug Discovery
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segment, and an intracellular carboxyl-terminal, except for β 1B (previously named β1A),
which is a β1 splice variant that lacks TM segment [64]. β1 and β3 interact with α subunit
noncovalently, whereas β2 and β4 bind to the α subunit via a disulfide bond. All β isoforms are
expressed in CNS, PNS, and cardiovascular systems, including excitable and nonexcitable
cells, where they are part of the V-set immunoglobulin superfamily of cell adhesion molecules
facilitating cell adhesion and cell migration. β1 is highly expressed in skeletal and cardiac
muscles, and the expression patterns of all β isoforms vary during development [65]. β sub-
units play broad role in modulating Nav function. They regulate expression and membrane
trafficking of α subunits, modulate channel activation and inactivation, and interfere with
toxin binding [66–68].
In 2017, the cryo-EM strucutre for EeNav1.4 in complex with the β1 subunit was determined
[12]. This structure provided a first glimpse into the interaction between α and β subunits. The
β1 subunit interacts with the α subunits as an ax, wherein its TM interacts with VSDIII within
the membrane as the handle, while its Ig domain as the head interacts with DI-L5 and DIV-L6
extracellular loops and the intervening segment between DIII S1 and S2 (Figure 4C and D).
Mutations in β subunits have been linked to many human diseases, including epilepsy, and
cardiac arrhythmia, and sudden death syndromes. Although β subunit-specific drugs have not
yet been developed, the Nav β subunit family remains a potential therapeutic target [68].
3. Channelopathy and therapeutic relevance
Nav channels are fundamentally important in a broad spectrum of physiological processes.
Not surprisingly, genetic mutations of Nav channels result in many debilitating to severe
phenotypes in CNS, PNS, cardiac, and neuromuscular systems. To date, at least 50 human
diseases have been attributed to aberrant activities of Nav channels; and hundreds of diseased
related mutations of α and the β subunits have been identified. These mutations lead to
channel dysfunctions called channelopathies (summarized in Table 2) and suggest the disease
association of respective channels.
3.1. Pain
Nav1.7, 1.8, and 1.9 are highly expressed in sensory neurons. They control the excitability of
nociceptive neurons, and thus are considered as therapeutic targets for pain relief [31, 71–74].
Among them, Nav1.7 was the first gene linked to human pain. In 2004, two missense muta-
tions, I848T and L858H in SCN9A (Nav1.7), were associated with edema, redness, warmth,
and bilateral pain in human inherited erythromelalgia (IEM) patients [75]. In 2006, three
nonsense mutations, S459X, I767X, and W897X, were identified in congenital insensitivity to
pain (CIP) patients [76]. Since then, additional gain-of-function mutations are associated with
IEM, paroxysmal extreme pain disorder (PEPD), small fiber neuropathy (SFN), and additional
loss-of-function mutations that are associated with CIP (Figure 6). The mechanism underlying
these conditions was unraveled by characterizing biophysical properties of disease mutations
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Isoform Channelopathies Discovered mutant
number
Discovery publication
number
SCN1A GEFS+2 Generalized epilepsy with febrile seizures plus 2 37 30
EIEE6 Epileptic encephalopathy, early infantile, 6 317 41
ICEGTC Intractable childhood epilepsy with generalized
tonic-clonic seizures
23 5
FHM3 Migraine, familial hemiplegic, 3 5 4
FEB3A Febrile seizures, familial, 3A 2 2
SCN2A BFIS3 Seizures, benign familial infantile 3 18 13
EIEE11 Epileptic encephalopathy, early infantile, 11 50 21
ASD Autism spectrum disorders 16 1
SCN3A CPE Cryptogenic partial epilepsy 4 1
ID Intellectual disability 1 1
AUTISM Autism 2 1
ADNSHL Autosomal dominant nonsyndromic hearing loss 14 1
SCN4A PMC Paramyotonia congenita of von Eulenburg 16 16
HOKPP2 Periodic paralysis hypokalemic 2 10 12
HYPP Periodic paralysis hyperkalemic 13 4
NKPP Periodic paralysis normokalemic 3 3
MYOSCN4A Myotonia SCN4A-related CMS16 14 13
CMS16 Myasthenic syndrome, congenital, 16 3 3
PAM Potassium-aggravated myotonias 6 1
SCN5A PFHB1A Progressive familial heart block 1A 4 6
LQT3 Long QT syndrome 3 123 30
BRGDA1 Brugada syndrome 1 197 33
SSS1 Sick sinus syndrome 1 VF1 2 3
VF1 Familial paroxysmal ventricular fibrillation 1 1 1
SIDS Sudden infant death syndrome 2 1
ATRST1 Atrial standstill 1 1 2
CMD1E Cardiomyopathy, dilated 1E 1 2
ATFB10 Atrial fibrillation, familial, 10 9 2
MEPPC Multifocal ectopic Purkinje-related premature
contractions
3 4
SCN8A EIEE13 Epileptic encephalopathy, early infantile, 13 44 15
BFIS5 Seizures, benign familial infantile, 5 1 2
SCN9A IEM Inherited erythermalgia (primary erythermalgia)
pain
23 11
CIP Congenital insensitivity to pain 13 1
PEPD Paroxysmal extreme pain disorder 9 3
GEFS+7 Generalized epilepsy with febrile seizures plus 7 2 1
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[76] and nociceptor-specific Nav1.7 knockout [77]. Together, these studies have established
that Nav1.7 is an essential and nonredundant requirement for nociception in humans.
While Nav1.7 is responsible for setting threshold for generation of action potentials, Nav1.8
and Nav1.9 contribute to the rising phase of action potentials in nociceptive neurons. Both
channels are expressed in small-diameter DRG neurons, which include the C fibers that
transmit nociceptive impulses [78]. Four gain-of-function Nav1.8 mutations (L554P, I1706V,
A1304T, G1662S) have been identified, which lead to an increase in excitability in small-
diameter neurons, underlying pain in small fiber neuropathy (SFN) [79–81]. In Nav1.9, gain-
of-function mutations were recently reported to be associated with pain, albeit with opposing
effects [82]. So far, naturally occurring loss-of-function mutations of Nav1.8 and Nav1.9 are yet
to be described in humans; Nav1.8 and 1.9 are clearly important in the pain pathology and
worth exploring as potential pain targets.
3.2. Epilepsy
Nav channel dysfunction is central to the pathophysiology of epileptic seizures, andmany of the
most widely used antiepileptic drugs, including phenytoin, carbamazepine, and lamotrigine,
Isoform Channelopathies Discovered mutant
number
Discovery publication
number
FEB3B Febrile seizures, familial, 3B 2 1
SFN Small fiber neuropathy 7 1
DS (SMEI) Dravet syndrome (severe myoclonic epilepsy of
infancy)
13 1
SCN10A FEPS2 Episodic pain syndrome, familial, 2 2 1
SFN Small fiber neuropathy 4 3
SCN11A HSAN7 Neuropathy, hereditary sensory, and autonomic, 7 2 2
FEPS3 Episodic pain syndrome, familial, 3 7 4
SFN Small fiber neuropathy 4 4
SCN1B ATFB13 Atrial fibrillation, familial, 13 2 1
BRGDA5 Brugada syndrome 5 1 1
EIEE52 Epileptic encephalopathy, early infantile, 52 2 2
GEFS+1 Generalized epilepsy with febrile seizures plus 1 2 3
SCN2B ATFB14 Atrial fibrillation, familial, 14 2 1
BRGDA Brugada syndrome 1 1
SCN3B ATFB16 Atrial fibrillation, familial, 16 4 2
BRGDA7 Brugada syndrome 7 1 1
SCN4B ATFB17 Atrial fibrillation, familial, 17 2 1
LQT10 Long QT syndrome 10 1 1
Table 2. Nav α and β subunits’ channelopathies data (updated in June, 2018 from database in http://www.uniprot.org).
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are Nav inhibitors. Many types of general epilepsy are resulted from mutations primarily
in Nav1.1, and also in other Nav α isoforms, including Nav1.2, Nav1.3, Nav1.6, Nav1.7, and
Nav β1. GEFS+ type 1 results from Nav β1 mutation C387G, which destroys extracellular
immunoglobulin domain and thus indirectly decreases rate of channel inactivation [83]. GEFS+
type 2 results from Nav1.1 mutations, such as T875 M (in DII-S4) and R1648H (in DIV-S4),
which decrease Nav1.1 inactivation rate directly [84]. Worth noting, some epilepsy-assicated
Nav1.2 and Nav1.6 mutations cause a gain-of-function when characterized in transfected cells
[85, 86]. Better understanding of clinical genetics and channel structure-function will facilitate
the drug development for Nav-associated neurological diseases.
3.3. Cardiac arrhythmias
Mutations of Nav1.5 have been linked to long QT syndrome (LQTS). Recent study suggests
that even modest depression of Nav1.5 expression may promote pathologic cardiac
remodeling and progression of heart failure [87]. Since the first LQT-related Nav1.5 mutation
being discovered in 1995 [88], more than a hundred Nav1.5 mutations that associate with
distinct cardiac rhythm disorders, such as LQT syndrome subtype 3, Brugada syndrome, and
cardiac conduction disease, have been identified [89]. These Nav1.5 mutations are spread out
the whole protein. Most Nav1.5 mutations change biophysical property by increasing persistent
Figure 6. Amino acid locations of Nav1.7 disease-related mutations on the Nav1.7 structure model. Modified from
[12, 31, 69–71].
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Na+ current or gain-of-function, while in Brugada syndrome and cardiac conduction disease,
most of the mutations are missense loss-of-function mutations. Because many mutations pro-
duce overlapping clinical phenotypes, it is crucial to understand genotype-phenotype correla-
tions in Nav1.5 channelopathies for drug development.
3.4. Neuromuscular diseases
Mutations of Nav1.4 channel are associated with inherited neuromuscular diseases. For exam-
ples, the M1592V mutation causes hyperkalemic periodic paralysis (HYPP), in which increased
levels of serum potassium lead to muscle hypoexcitability and paralysis; the R1448C mutation
causes paramyotonia congenita (PMC), which is induced by cold and aggravated by increased
muscle activity; and the G1306A mutation causes potassium-aggravated myotonias (PAM).
These mutations affect either voltage-dependent activation or inactivation of Nav1.4, and are
inherited in an autosomal dominant manner [90]. In contrast, most Nav1.6 mutations are
recessive. An allelic mutation A107T in DIII S4-S5 caused ataxic phenotype by shifting Nav1.6
activation and inactivation to about 14 mV in the depolarizing direction, suggesting Nav1.6 is
required for the complex spiking of cerebellar Purkinje cells and for persistent sodium current
in several classes of neurons [91–93].
4. Nav modulation with small and large molecules
Nav channels have long been recognized as targets for treating pain, neurological disorders,
and cardiac arrhythmias. In nature, Nav channels are the molecular targets of a broad range of
neurotoxins including tetrodotoxin (TTX), saxitoxin (STX), veratridine (VTD), and batracho-
toxin (BTX) from marine bacteria and plants, as well as peptide toxins such as ProToxin
(ProTX), Huwentoxin (HwTX and α-ScTxs) from the venoms of scorpions, spiders, sea anem-
ones, and cone snails. Additionally, many Nav-targeting drugs have been developed, includ-
ing local anesthesia (LA), antiarrhythmics (e.g., lidocaine, mexiletine), anticonvulsants (e.g.,
carbamazepine), and antidepressants (e.g., amitriptyline). In general, these drugs do not have
subtype selectivity and have small therapeutic index. Recently, two series of highly isoform-
selective compounds, aryl sulfonamides for Nav1.7 and phenyl imidazole for Nav1.8, have
been reported [94, 95]. Besides small molecules, monoclonal antibody has also been proposed
as an alternative strategy. Nonetheless, due to the high-sequence homology among all Nav
isoforms, subtype selective targeting remains a challenge.
All nature or synthesized small and large modulators for Nav channels can be classified as pore
blockers or gating modifiers. Pore blockers (e.g., TTX) physically occlude the pore, thereby
inhibiting channel conductance. Often the blockade is tonic, or independent of states of the
channels. Gating modifiers (aryl sulfonamides as example) preferentially modify activated or
inactivated states, thus reducing currents progressively with increased stimulation duration and
frequency.
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Based on their drug binding sites, Nav inhibitors can be classified into different groups
(Figure 7 and Table 3).
Site 1: extracellular pore blocker. This site is formed by the four P-loops and represents the
binding site of two known groups of pore blockers, including small molecular guanidinium
toxins frommarine bacteria (TTX and STX), and 17–25 amino acids’ peptide μ-conotoxins from
marine cone snail toxins [96–98]. These toxins physically plug the pore and thereby inhibit the
sodium conductance.
Site 2: intracellular pore gating activator (state dependent). The binding site is the fenestra-
tion site formed between DI-S6 and DIV-S6, which binds to many small lipid-soluble toxins
including batrachotoxin (BTX) from frog, antillatoxin (ATX) from marine species, and veratri-
dine (VTD), aconitine (ACT), and grayanotoxin (GTX) from plants. These modulators facilitate
channel activation or prevent inactivation, thereby increasing channel conductance. They often
have much higher affinity to the open and inactivated states of Nav channel as the binding
fenestration exposed.
Site 3: extracellular gating activator. The binding site is localized in the DIV S3-S4 extracellu-
lar loop for two groups of peptide toxin activators: scorpion α-toxins (α-ScTxs) and sea. Upon
binding, these modulators prevent the movement of DIV-S4, thus inhibiting transition to fast
inactivation.
Site 4: extracellular gating blocker. The binding site is the DII S1-S2 and S3-S4 extracellular
loop, which binds to four groups of peptide toxin blockers, including β-scorpion toxins
(β-ScTxs), β-spider toxins, μO-conotoxins, and ι-conotoxins. In general, these toxins block the
DII-VSD conformational change and shift the voltage dependence of activation toward more
hyperpolarized potentials, though the structural-based mechanism of action is not clear.
Figure 7. Nav channel structural topology with drug binding sites. Domain DI/II/III/IV is colored orange, yellow, cyan,
and blue, respectively. The IFM fast inactivation gate is shown in red sphere format. All currently identified eight Nav
binding sites are labeled corresponding to its visibility. Binding sites leading to channel activation are in green, and
binding sites leading to channel blockage are in gray. Seven natural toxin binding sites are labeled with oval, while local
anesthetic, aryl sulfonamide, and phenyl imidazole binding sites are labeled with diamonds.
Voltage-Gated Sodium Channels in Drug Discovery
http://dx.doi.org/10.5772/intechopen.78256
29
Binding
site
Molecule group Effect and
application
Molecule
examples
Structure or peptide
PDB
Reference
Site 1. DI–
IV P-loop
Marine bacteria toxin Block Na+
conduction
Tetrodotoxin (TTX) [96]
Saxitoxin (STX) [97]
μ-Conotoxin KIIIA 17 aa, 2LXG [98]
PIIIA, PIIIB 22 aa, 1R9I [98]
GIIIA, GIIIB 23 aa, 1TCG [98]
BuIIIB 25 aa, 2LOC [98]
SmIIIA 22 aa, 1Q2J [98]
Site 2. DI
DIV S6
Small lipid-soluble toxins Prevent
inactivation Nav
agonist
Batrachotoxin
(BTX)
[102]
Veratridine (VTD) [103]
Aconitine (ACT) [104]
Antillatoxin (ATX) [105]
Grayanotoxin
(GTX)
[106]
Site 3.
DIV-S3-S4
α-Scorpion toxins Prevent
inactivation
Aah 2 64 aa, 1SEG [107]
Nav agonist LqhaIT 65 aa, 1LQH [107]
LqhIT2 62 aa, 2I61 [107]
BMK MI 64 aa, 1SN1 [107]
Sea anemone toxins Type I: ATXI, etc. 46 aa, 1ATX [108]
Type II: Rp2, etc. 48 aa [108]
Type III: ATX3, etc. 27 aa, 1ANS [108]
Site 4. DII
S3–S4
β-Scorpion toxins (β-ScTxs) Prevent
activation
Cn2 67 aa, 1CN2 [109]
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Binding
site
Molecule group Effect and
application
Molecule
examples
Structure or peptide
PDB
Reference
Ts1 (=Ts7, TsVII,
Tsγ)
61 aa, 1B7D [109]
Bj-xtrIT 77 aa, 1BCG [109]
LqhIT2 62 aa, 2I61 [109]
β-Spider toxins ProTXI 35 aa, 2M9L [110]
ProTX II 30 aa, 2N9T [110]
HwTX-IV 35 aa, 1MB6 [111]
Magi 5 29 aa, 2GX1 [112]
μO-conotoxins μO-MrVIB 31 aa, 1RMK [113]
ι-conotoxins ι-RxIA 38 aa, 2JTU [113]
Site 5. DI
S6
Cyclic polyethers
(dinoflagellate toxin)
Prevent
inactivation, Nav
agonist
Brevetoxins (PbTx) [114]
Ciguatoxins
(CTX1)
[101]
Site 6.
DIV S4
Cysteine knot 3 disulfide
bridges
Conotoxins Nav
agonist
δ-TxVIA 27 aa, 1FU3 [115]
δ-EVIA 33 aa, 1G1P [113]
Site 7.
(LA) DIV
S6
Local anesthetics Local anesthetics
Class Ib
antiarryhythmic
Neoropathic pain
Lidocaine [116]
State-dependent
nonselective Na+ conduction
blockers
Antidepressant Carbamazepine [116]
Antidepressant Amitriptyline [117]
Anticonvulsant Lamotrigine [118]
Local anesthetic Tetracaine [119]
Class Ia
antiarrhythmic
Quinidine [120]
Class Ic
antiarrhythmic
Flecainide [121]
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Site 5: intracellular pore gating activator (state dependent). The fenestration site between DI-
S6 and DIV-S5 binds two classes of cyclic polyether toxins from dinoflagellate: brevetoxins
(PbTx) and ciguatoxins (CTX). These modulators have higher affinity to activated channel.
Upon binding, they shift the activation and inactivation both to more hyperpolarizing voltage,
thus keeping the channel hyperactive.
Site 6: extracellular gating activator. The DIV-S4 fenestration binds to δ-conotoxins causing
similar effects as site 3 toxins by slowing or inhibiting inactivation. Although sites 6 and 3 are
structurally close to each other, however, the two categories activators do not compete with
each other [99]. Site 6 activators trap DIV-S4 in outward conformation, thus leading to a
persistent activation and prolongation of action potential.
Site 7: local anesthetic (LA) binding site. The inner cavity of channel pore, consisting of amino
acid residues in S6 of DI, DIII, and DIV, forms the LA binding site. The LA binding site is
highly conserved across Nav channels and accounts for the lack of subtype selectivity for most
clinically used sodium channel blockers.
Binding
site
Molecule group Effect and
application
Molecule
examples
Structure or peptide
PDB
Reference
Site 8. DII
S2
Cysteine knot Conotoxins Nav
antagonist
μO§-GVIIJ 35 aa, 2N8H [100]
Site 9.
DIV S4
Aryl sulfonamides Nav1.7 selective
blockers
ICA-121431
(Icagen)
[101]
PF-04856264
(Pfizer)
[101]
PF-05089771
(Pfizer)
[122]
GX-936 [123]
Site 10 Phenyl imidazole Nav1.8 selective
blockers
A-803467 [124]
PF-04531083
(Pfizer)
[95]
Table 3. Small molecules and toxin modulators for Nav channels.
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Site 8: extracellular gating blocker. The site was identified by studying a class of cone snail
μO§-conotoxins blockers, such as μO§-GVIIJ. The putative binding site is close to a cysteine
near DII P-loop (C910 in rNav1.2), which is responsible of the antagonist effect [100].
Site 9: aryl sulfonamide site. The unique Nav1.7 VSD4 binding site for the new series of aryl
sulfonamide compounds, such as ICA-121431, PF-04856264 [101].
Site 10: phenyl imidazole site. The unique fenestration-selectivity filter site in Nav1.8 for the
new series of phenyl imidazole compounds, such as A-803467, PF-04531083 [95].
5. Concluding remarks
Voltage-gated sodium channels play essential roles in physiological function, and historically,
sodium channel blockers have been developed as local anesthetics and anticonvulsants. How-
ever, these early generation of sodium channel drugs were developed decades ago without the
exact understanding of their molecular targets and mechanisms of action; their general lack of
on-target potency and off-target selectivity renders narrow therapeutic windows. In recent
years, several scientific frontiers have been rapidly evolving. First, the physiological functions
of each sodium channel have been determined. Second, their associations to human diseases
have been revealed in the form of “channelopathies.” Often both gain-of-function and loss-of-
function mutations have been linked to human diseases, therefore pinpointing exactly the
molecular targets. Third, the structural determination of sodium channels provides opportu-
nities for structural-based drug design. Together, these progresses have ushered in a new,
exciting era of sodium channel drug discovery.
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